News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

Pathologists Take Note: IBM’s Watson to Attack Cancer with Help of WellPoint and Cedars-Sinai

Goal of unique collaboration is to give physicians a more accurate way to diagnose and treat many types of cancer

Two noteworthy healthcare organizations will collaborate with IBM (NYSE: IBM) to explore how IBM’s Watson can be used to help physicians deliver improved outcomes to patients. The collaboration involves one major health insurer and a prominent academic medical center in Los Angeles.

WellPoint, Inc. (NYSE: WLP) will interact with oncology experts at the Cedars-Sinai Cancer Institute in Los Angeles to “educate” and program Watson as a physician’s assistant. What makes this particularly interesting for anatomic pathologists is the potential of this project to marry advances in molecular diagnostics with artificial intelligence in ways that allow physicians to diagnose different cancers earlier and with greater accuracy.

In its story about this development, the Los Angeles Times reported that, per IBM, physicians at Cedars-Sinai Medical Center’s Samuel Oschin Comprehensive Cancer Institute will be the first to use the Watson technology.

The institute’s doctors will serve as advisers and lend expertise to help shape the initiative to develop effective ways to use Watson. “Cedars Sinai will provide the guidelines and insights to put into Watson,” stated Manoj Saxena, General Manager of IBM Watson Solutions, in a story published by Forbes Magazine.

Watson is IBM’s computing system that incorporates deep question answering technology that allows it to search quickly through vast amounts of data, then process it and analyze it in a way similar to that of the human brain. The Watson system is capable of processing the equivalent of about 200 million pages of data in about three seconds, Forbes reported.

(more…)

WellPoint’s New Pay-for-Performance Program to Pay Hospitals More for Meeting Quality Measures

Private payers taking first steps on a path toward value-based purchasing that could eventually include clinical pathology laboratory testing services

Pay-for-performance just took a leap forward with news that one of the nation’s largest health insurers will link hospital reimbursement to specific quality measures. This development could be a precursor to similar payer initiatives that involve how private payers reimburse clinical laboratories and anatomic pathology groups.

Indianapolis-based WellPoint, Inc. (NYSE: WLP) will revamp the way it reimburses about 1,500 hospitals across the country. In a news story published by Bloomberg Businessweek, Rick Wartzman, Executive Director of the Drucker Institute at Claremont Graduate University, explained that, going forward, WellPoint wants to base annual payment increases to hospitals using a formula that incorporates the health insurer’s quality criteria, rather than to the quantity of services delivered.
(more…)

;